Why the study?
Does intravenous sotalol affect His-Purkinje conduction and refractoriness in patients with coronary artery disease undergoing electrophysiologic studies?
Does intravenous sotalol affect His-Purkinje conduction and refractoriness in patients with coronary artery disease undergoing electrophysiologic studies?
Answers are grounded in this paper and cite their sources.
Intravenous sotalol increases His-Purkinje refractoriness without affecting conduction, highlighting the need for cautious use in patients with diseased His-Purkinje systems due to the risk of distal atrioventricular block at fast heart rates.
Background: The effects of sotalol on refractoriness in human ventricular and atrial muscles have been well established, but the drug's effect on the electrical properties of the His- Purkinje system in humans is not known, especially whether sotalol's effect is due solely to its action on prolonging repolarization or in combination with its beta-blocking properties. We studied the electrophysiologic effects of intravenous sotalol and propranolol in patients undergoing electrophysiologic studies of cardiac arrhythmias. Methods and Results: We studied 22 patients (19 men, 3 women; mean age, 60 ± 6 years) who had coronary artery disease and assessable anterograde, retrograde, or both, His-Purkinje system function. Fifteen patients underwent electrophysiologic studies before and after intra venous sotalol (1.5 mg/kg), and 7 patients underwent electrophysiologic studies before and after intravenous propranolol (0.15 mg/kg). Both sotalol and propranolol had no signilicant effect on the H-V interval, but sotalol significantly increased ventricular refractoriness and His-Purkinje refractoriness, both in anterograde and retrograde conduction, whereas propra nolol did not. Sotalol's effect on His-Purkinje refractoriness also caused alrioventricular block distal to the His bundle during atrial pacing at a moderately fast rate. Sotalol was not effec tive in preventing bundle branch re-entry tachycardia, nevertheless. it increased cycle length of bundle branch re-entry tachycardia by increasing refractoriness. Conclusions: Sotalol increased His-Purkinje refractoriness in humans but had no effect on His-Purkinje conduction. The drug must be used judiciously in patients with a diseased His- Purkinje system because it may cause atrioventricular block distal to His at fast heart rates. Sotalol had no effect on macrore-entry utilising bundle branches.
No takes yet. Share an insight, caveat, or question.
Nademanee et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: